Physician profile
Daniel Vanroy
NPI 1740236330
$22,599.14
in general payments reported to CMS, 2019-2025
35 companies · $820 in 2025
The $820 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,812 · 2020: $1,570 · 2021: $1,883 · 2022: $1,648 · 2023: $2,429 · 2024: $5,437 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,686 · Travel and Lodging: $4,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,686.24 |
| Travel and Lodging | $3,999.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,241.92 | 2021-2025 | Onyx Frontier, Symplicity G3, Cobalt Dr Mri Surescan |
| Abbott Laboratories | $4,572.26 | 2019-2024 | Xience Sierra, Aveir |
| Medtronic Vascular, INC. | $1,875.59 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $1,722.65 | 2019-2023 | Gore Tag Conformable Thoracic Stent Graft, Gore Tag Thoracic Branch Endoprosthesis |
| Penumbra, INC. | $1,518.13 | 2019-2025 | Indigo System, Penumbra System |
| Cook Medical LLC | $1,500.99 | 2019-2025 | Cook, Rosen, Advance |
| Siemens Medical Solutions USA, INC. | $1,224.59 | 2019 | |
| Amgen INC. | $759.19 | 2019-2025 | Repatha, Repatha |
| Abiomed | $733.81 | 2021-2025 | |
| Boston Scientific Corporation | $517.24 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $484.68 | 2019-2025 | |
| Bard Peripheral Vascular, INC. | $384.16 | 2020-2024 | Venovo, True Flow, Lutonix Drug Coated Balloon |
| Cardiovascular Systems INC. | $296.37 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $243.05 | 2019-2024 | Xarelto |
| Angiodynamics, INC. | $230.47 | 2022-2025 | Auryon Laser System 100-120 Vac |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $179.78 | 2019-2025 | Eliquis, Camzyos |
| Shockwave Medical, INC | $148.97 | 2021 | |
| Limflow INC. | $134.62 | 2023 | Limflow System |
| Stryker Corporation | $133.90 | 2025 | Limflow System |
| Edwards Lifesciences Corporation | $116.46 | 2019 | |
| Pfizer INC. | $94.16 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $86.76 | 2022-2024 | Verquvo |
| Silk Road Medical, INC. | $71.97 | 2023-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Lexicon Pharmaceuticals, INC. | $50.84 | 2023-2024 | Inpefa |
| Livanova USA, INC. | $48.29 | 2022 | |
| Cvrx, INC. | $44.77 | 2025 | Barostim Neo System |
| Organogenesis INC. | $41.46 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.13 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.37 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.58 | 2025 | Evkeeza |
| Astrazeneca Pharmaceuticals Lp | $19.86 | 2025 | Brilinta |
| Kiniksa Pharmaceuticals International, Plc | $17.28 | 2024 | Arcalyst |
| Kerecis Limited | $13.57 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Cardiva Medical, INC. | $13.27 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Vanroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.